The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma.

ABSTRACT:

Purpose

This study aimed to explore the relationship between plakoglobin expression and clinical data in the patients with surgically resected lung adenocarcinoma.

Results

With follow-up of median 50.14 months, the average PFS and OS were 16.82 and 57.92 months, respectively. In 147 patients, recurrence or death was observed in 131 patients. According to the log-rank test, low plakoglobin expression was a significant predictor for favorable DFS (P=0.006) and OS (P=0.043). For the analyses within subgroups, high plakoglobin expression was an independent factor for reducing DFS in non-metastatic patients with resected lung adenocarcinoma (P < 0.05). Moreover, high plakoglobin expression was associated with poor DFS even receiving adjuvant chemotherapy (P =0.028) and with a sho

SUBMITTER: He X 

PROVIDER: S-EPMC4924786 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature